← Back to Search

Vitamin D Analog

Zemplar for Type 2 Diabetes

N/A
Waitlist Available
Research Sponsored by Scott and White Hospital & Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 4 weeks, and 12 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

The purpose of this research study is to study the effects of paricalcitol on endothelial function and inflammation, cardiovascular risk factors which are associated with patient populations that have Type 2 diabetes and Stage 3 and 4 Chronic Kidney Disease (CKD). Hypothesis 1: The state of CKD is associated with oxidative stress and inflammation and impaired post ischemic endothelium dependent flow mediated vasodilation which may contribute to atherogenesis. Hypothesis 2: The administration of paracalcitol to patients with CKD will suppress oxidative stress and inflammation and improve endothelial function and thus contribute to an anti-atherogenic action.

Eligible Conditions
  • Type 2 Diabetes
  • Chronic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 4 weeks, and 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 4 weeks, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The change in brachial artery Flow Mediated Dilataion with paracalcitol (1mcg/day)compared with placebo for 3 months.
Secondary study objectives
Biomarker Measurement

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ZemplarActive Control1 Intervention
Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Group II: PlaceboPlacebo Group1 Intervention
Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months

Find a Location

Who is running the clinical trial?

Scott and White Hospital & ClinicLead Sponsor
22 Previous Clinical Trials
32,424 Total Patients Enrolled
AbbottIndustry Sponsor
752 Previous Clinical Trials
478,075 Total Patients Enrolled
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top